Not yet recruiting
Validation Of anatomY-specific Aortic Valve Implantation Guided by Software Using EncantoR
NCT07696182· Abbott Medical Devices· Source
Contact: Nadia Bouhdi
Recruiting
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07441200· Phase 2· NS Pharma, Inc.· Source
Recruiting
Methotrexate Treatment in Hand Osteoarthritis Refractory to Usual Treatments
NCT07501507· Phase 2/3· Centre Hospitalier Universitaire de Nice· Source
Not yet recruiting
Impact of discontinuation of long-term macrolides in stable Non Cystic Fibrosis Bronchiectasis : a multicenter randomized controlled trial
2025-521493-33-00· Phase 3· Centre Hospitalier Intercommunal Creteil· Source
Not yet recruiting
Tdose Binding and Tocilizumab
NCT07582185· Phase 4· Centre Hospitalier Universitaire de Nice· Source
Recruiting
Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer
NCT07124858· Federation Francophone de Cancerologie Digestive· Source
Contact: HERVE PERRIER
Recruiting
Pancreatic cancer first-line NALIRIFOX optimization with 5-FU maintenance and role of antibiotics and microbiota exploration in second-line treatment – A non-comparative, randomized phase II PANORAMIX GERCOR G-116 PRODIGE 105 study
2024-517766-41-00· Phase 2· Association Gercor· Source
Recruiting
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07225569· Phase 2· Sanofi· Source
Recruiting
Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX
NCT07044453· Phase 2/3· University Hospital, Rouen· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Recruiting
Early intervention in plaque psoriasis: is bimekizumab able to delay chronic inflammation?
Prospective multicenter interventional study
2024-514647-29-01· Phase 2· Centre Hospitalier Universitaire De Nice· Source
Recruiting
Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?
NCT06742333· Phase 2· Centre Hospitalier Universitaire de Nice· Source
Contact: Nathalie QUILES-TSIMARATOS, Ph
Not yet recruiting
Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial
NCT06263816· Phase 3· University Hospital, Tours· Source
Recruiting
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial
2024-510772-20-00· Phase 2· Centre Hospitalier Universitaire De Dijon· Source
Not yet recruiting
Corticoid Therapy in Acute Myocarditis
NCT06522100· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
2024-512895-36-00· Phase 3· Akero Therapeutics Inc.· Source
Recruiting
Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment
NCT07117981· Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts· Source
Contact: Antoine POULER, DR
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis
NCT06368804· Phase 2· Centre Hospitalier Intercommunal Creteil· Source
Recruiting
FLUOCOL-1 : Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage
NCT05168839· Phase 4· Centre Hospitalier Regional Universitaire· Source
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357· Phase 3· AstraZeneca· Source
Active, not recruiting
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizumab) and
immunotherapy ( Pembrolizumab)
NCT04262687· Phase 2· Fondation Franc.Cancerologie Digestive· Source
Active, not recruiting
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
2023-508235-31-00· Phase 3· Almirall S.A.· Source
Recruiting
DVT Burden and the Risk of Post-thrombotic Syndrome
NCT06385353· Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer· Source
Contact: Benjamin Ally, MD
Recruiting
Trial Evaluating the Rate of Pneumothorax in Severe Emphysema Secondary to Endoscopic Volume Reduction With Two-stage ZEPHYR® Valves Versus Endoscopic Volume Reduction With One-stage ZEPHYR® Valves
NCT06181357· University Hospital, Limoges· Source
Contact: Yoann AMMAR, MD
Active, not recruiting
TocilizuMab discontinuAtion in GIant Cell Arteritis
2023-505515-21-00· Phase 3· Centre Hospitalier Universitaire De Dijon· Source
Recruiting
A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
NCT06541652· Federation Francophone de Cancerologie Digestive· Source
Contact: XAVIER ADHOUTE, MD
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
2023-505141-48-00· Phase 3· Akero Therapeutics Inc.· Source
Active, not recruiting
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
NCT05925530· Phase 2· AstraZeneca· Source
Not yet recruiting
Comparison Between Intra-articular Infiltrations of PRP, MFAT, and PRP-MFAT in the Treatment of Symptomatic Knee Osteoarthritis.
NCT06084637· Phase 3· Assistance Publique Hopitaux De Marseille· Source
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· Phase 3· Amgen· Source
Active, not recruiting
Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an AI Software During AF Ablation
NCT06083012· Volta Medical· Source
Completed
Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions
NCT05622071· Phase 2· UNICANCER· Source
Active, not recruiting
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
NCT05476796· Phase 2· UNICANCER· Source
Recruiting
Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer
NCT05706779· Phase 2· Federation Francophone de Cancerologie Digestive· Source
Active, not recruiting
Phase 1b study investigating the association of NP137 with Atezolizumab-Bevacizumab combination in first line in unresectable hepatocellular carcinoma
2022-500903-38-00· Phase 1· University Hospital Grenoble· Source
Recruiting
Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma
NCT05429138· Assistance Publique Hopitaux De Marseille· Source
Contact: Elodie ARCHIER (sub-investigator)
Recruiting
Evaluation of Lung Cancer CT Screening Performance Among Former and Current Smokers
NCT05486455· Hospital St. Joseph, Marseille, France· Source
Contact: Cécile BIELMANN
Active, not recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Recruiting
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction
NCT05255302· Phase 2/3· Intergroupe Francophone de Cancerologie Thoracique· Source
Active, not recruiting
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
NCT05201547· Phase 3· ARCAGY/ GINECO GROUP· Source
Active, not recruiting
Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and severe bleeding: a randomized, multicentre trial (IVIORDEX).
NCT04968899· Phase 3· Assistance Publique Hopitaux De Paris· Source
Recruiting
Interest of the Immunoscore® as a Post-operative Complementary Tool for the Detection of the Risk of Recurrence in Patients With Nonmetastatic Colorectal Cancer
NCT04938986· Hospital St. Joseph, Marseille, France· Source
Contact: Hervé PERRIER
Active, not recruiting
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728· Phase 3· Inventiva Pharma· Source
Active, not recruiting
Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis
NCT04870203· Phase 3· University Hospital, Bordeaux· Source
Active, not recruiting
Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxycholic acid therapy (BEZASCLER
NCT04309773· Phase 3· Assistance Publique Hopitaux De Paris· Source
Active, not recruiting
Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial
NCT04727307· Phase 2· University Hospital, Montpellier· Source
Active, not recruiting
Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism (MAJIK)
NCT04602091· Societe Francaise de Rhumatologie· Source
Active, not recruiting
Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)
NCT04075981· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Showing 50 of 58.